Literature DB >> 33525489

Assessment of a 4-Week Starch- and Sucrose-Reduced Diet and Its Effects on Gastrointestinal Symptoms and Inflammatory Parameters among Patients with Irritable Bowel Syndrome.

Clara Nilholm1, Ewa Larsson1, Emily Sonestedt2, Bodil Roth1, Bodil Ohlsson1.   

Abstract

Dietary advice constitutes a treatment strategy for irritable bowel syndrome (IBS). We aimed to examine the effect of a starch- and sucrose-reduced diet (SSRD) on gastrointestinal symptoms in IBS patients, in relation to dietary intake and systemic inflammatory parameters. IBS patients (n = 105) were randomized to a 4-week SSRD intervention (n = 80) receiving written and verbal dietary advice focused on starch and sucrose reduction and increased intake of protein, fat and dairy, or control group (n = 25; habitual diet). At baseline and 4 weeks, blood was sampled, and participants filled out IBS-SSS, VAS-IBS, and Rome IV questionnaires and dietary registrations. C-reactive protein and cytokines TNF-α, IFN-γ, IL-6, IL-8, IL-10, and IL-18 were analyzed from plasma. At 4 weeks, the intervention group displayed lower total IBS-SSS, 'abdominal pain', 'bloating/flatulence' and 'intestinal symptoms´ influence on daily life' scores (p ≤ 0.001 for all) compared to controls, and a 74%, responder rate (RR = ΔTotal IBS-SSS ≥ -50; RRcontrols = 24%). Median values of sucrose (5.4 vs. 20 g), disaccharides (16 vs. 28 g), starch (22 vs. 82 g) and carbohydrates (88 vs. 182 g) were lower for the intervention group compared to controls (p ≤ 0.002 for all), and energy percentages (E%) of protein (21 vs. 17 E%, p = 0.006) and fat (47 vs. 38 E%, p = 0.002) were higher. Sugar-, starch- and carbohydrate-reductions correlated weakly-moderately with total IBS-SSS decrease for all participants. Inflammatory parameters were unaffected. IBS patients display high compliance to the SSRD, with improved gastrointestinal symptoms but unaltered inflammatory parameters. In conclusion, the SSRD constitutes a promising dietary treatment for IBS, but needs to be further researched and compared to established dietary treatments before it could be used in a clinical setting.

Entities:  

Keywords:  IBS; dietary intervention; inflammation; starch; sucrose

Year:  2021        PMID: 33525489      PMCID: PMC7911460          DOI: 10.3390/nu13020416

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  36 in total

Review 1.  British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update).

Authors:  Y A McKenzie; R K Bowyer; H Leach; P Gulia; J Horobin; N A O'Sullivan; C Pettitt; L B Reeves; L Seamark; M Williams; J Thompson; M C E Lomer
Journal:  J Hum Nutr Diet       Date:  2016-06-08       Impact factor: 3.089

Review 2.  Non-celiac gluten or wheat sensitivity: It's complicated!

Authors:  Maria I Pinto-Sanchez; Elena F Verdu
Journal:  Neurogastroenterol Motil       Date:  2018-08       Impact factor: 3.598

Review 3.  Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndrome-directions for future research.

Authors:  Hannah Mitchell; Judi Porter; Peter R Gibson; Jacqueline Barrett; Mayur Garg
Journal:  Aliment Pharmacol Ther       Date:  2019-01       Impact factor: 8.171

4.  Further validation of the visual analogue scale for irritable bowel syndrome after use in clinical practice.

Authors:  Mariette Bengtsson; Jesper Persson; Kristina Sjölund; Bodil Ohlsson
Journal:  Gastroenterol Nurs       Date:  2013 May-Jun       Impact factor: 0.978

Review 5.  Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators.

Authors:  Juan J Martin-Viñas; Eamonn M M Quigley
Journal:  J Dig Dis       Date:  2016-09       Impact factor: 2.325

6.  Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome.

Authors:  Maria Henström; Lena Diekmann; Ferdinando Bonfiglio; Fatemeh Hadizadeh; Eva-Maria Kuech; Maren von Köckritz-Blickwede; Louise B Thingholm; Tenghao Zheng; Ghazaleh Assadi; Claudia Dierks; Martin Heine; Ute Philipp; Ottmar Distl; Mary E Money; Meriem Belheouane; Femke-Anouska Heinsen; Joseph Rafter; Gerardo Nardone; Rosario Cuomo; Paolo Usai-Satta; Francesca Galeazzi; Matteo Neri; Susanna Walter; Magnus Simrén; Pontus Karling; Bodil Ohlsson; Peter T Schmidt; Greger Lindberg; Aldona Dlugosz; Lars Agreus; Anna Andreasson; Emeran Mayer; John F Baines; Lars Engstrand; Piero Portincasa; Massimo Bellini; Vincenzo Stanghellini; Giovanni Barbara; Lin Chang; Michael Camilleri; Andre Franke; Hassan Y Naim; Mauro D'Amato
Journal:  Gut       Date:  2016-11-21       Impact factor: 23.059

7.  Identification of Inflammatory and Disease-Associated Plasma Proteins that Associate with Intake of Added Sugar and Sugar-Sweetened Beverages and Their Role in Type 2 Diabetes Risk.

Authors:  Stina Ramne; Isabel Drake; Ulrika Ericson; Jan Nilsson; Marju Orho-Melander; Gunnar Engström; Emily Sonestedt
Journal:  Nutrients       Date:  2020-10-14       Impact factor: 5.717

8.  Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS).

Authors:  Mariette Bengtsson; Bodil Ohlsson; Kerstin Ulander
Journal:  BMC Gastroenterol       Date:  2007-05-03       Impact factor: 3.067

9.  An Okinawan-based Nordic diet improves anthropometry, metabolic control, and health-related quality of life in Scandinavian patients with type 2 diabetes: a pilot trial.

Authors:  Gassan Darwiche; Peter Höglund; Bodil Roth; Ewa Larsson; Trygve Sjöberg; Björn Wohlfart; Stig Steen; Bodil Ohlsson
Journal:  Food Nutr Res       Date:  2016-09-22       Impact factor: 3.894

View more
  8 in total

Review 1.  Carbohydrate Maldigestion and Intolerance.

Authors:  Fernando Fernández-Bañares
Journal:  Nutrients       Date:  2022-05-04       Impact factor: 6.706

Review 2.  Functional bowel symptoms in the general population (Review).

Authors:  Bodil Ohlsson
Journal:  Mol Med Rep       Date:  2022-05-20       Impact factor: 3.423

3.  A Starch- and Sucrose-Reduced Diet in Irritable Bowel Syndrome Leads to Lower Circulating Levels of PAI-1 and Visfatin: A Randomized Controlled Study.

Authors:  Bodil Roth; Julia Myllyvainio; Mauro D'Amato; Ewa Larsson; Bodil Ohlsson
Journal:  Nutrients       Date:  2022-04-19       Impact factor: 6.706

Review 4.  Theories behind the effect of starch‑ and sucrose‑reduced diets on gastrointestinal symptoms in irritable bowel syndrome (Review).

Authors:  Bodil Ohlsson
Journal:  Mol Med Rep       Date:  2021-08-20       Impact factor: 2.952

5.  A starch- and sucrose-reduced dietary intervention in irritable bowel syndrome patients produced a shift in gut microbiota composition along with changes in phylum, genus, and amplicon sequence variant abundances, without affecting the micro-RNA levels.

Authors:  Clara Nilholm; Lokeshwaran Manoharan; Bodil Roth; Mauro D'Amato; Bodil Ohlsson
Journal:  United European Gastroenterol J       Date:  2022-04-28       Impact factor: 6.866

6.  Poor intake of vitamins and minerals is associated with symptoms among patients with irritable bowel syndrome.

Authors:  Bodil Roth; Ewa Larsson; Bodil Ohlsson
Journal:  J Gastroenterol Hepatol       Date:  2022-04-05       Impact factor: 4.369

Review 7.  Effect of Important Food Sources of Fructose-Containing Sugars on Inflammatory Biomarkers: A Systematic Review and Meta-Analysis of Controlled Feeding Trials.

Authors:  XinYe Qi; Laura Chiavaroli; Danielle Lee; Sabrina Ayoub-Charette; Tauseef A Khan; Fei Au-Yeung; Amna Ahmed; Annette Cheung; Qi Liu; Sonia Blanco Mejia; Vivian L Choo; Russell J de Souza; Thomas M S Wolever; Lawrence A Leiter; Cyril W C Kendall; David J A Jenkins; John L Sievenpiper
Journal:  Nutrients       Date:  2022-09-26       Impact factor: 6.706

8.  Metabolic Profiling of Plasma in Patients with Irritable Bowel Syndrome after a 4-Week Starch- and Sucrose-Reduced Diet.

Authors:  Hans Stenlund; Clara Nilholm; Elin Chorell; Bodil Roth; Mauro D'Amato; Bodil Ohlsson
Journal:  Metabolites       Date:  2021-07-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.